Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia

Ferreira, AM; Marques da Silva, P

http://hdl.handle.net/10400.17/2598

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
AJCDis 169.pdf		502.23 KB	Adobe PDF	Download

Send Feedback

Authors

Ferreira, AM

Marques da Silva, P

Abstract(s)

Statin-ezetimibe combinations are a potentially advantageous therapeutic option for high-risk patients who need additional lowering of low-density lipoprotein cholesterol (LDL-C). These combinations may overcome some of the limitations of statin monotherapy by blocking both sources of cholesterol. Recently, a fixed-dose combination with atorvastatin, one of the most extensively studied statins, was approved and launched in several countries, including the USA. Depending on atorvastatin dose, this combination provides LDL-C reductions of 50-60%, triglyceride reductions of 30-40%, and high-density lipoprotein cholesterol (HDL-C) increases of 5-9%. Studies comparing the lipid-lowering efficacy of the atorvastatin-ezetimibe combination with the alternatives of statin dose titration or switching to a more potent statin consistently showed that combination therapy provided greater LDL-C reduction, translating into a greater proportion of patients achieving lipid goals. Simvastatin-ezetimibe combinations have been shown to reduce the incidence of major atherosclerotic events in several clinical settings to a magnitude that seems similar to that observed with statins for the same degree of absolute LDL-C lowering. The atorvastatin-ezetimibe combination has also been shown to induce the regression of coronary atherosclerosis measured by intravascular ultrasound in a significantly greater proportion of patients than atorvastatin alone. Atorvastatin-ezetimibe combinations are generally well tolerated. Previous concerns of a possible increase in the incidence of cancer with ezetimibe were dismissed in large trials with long follow-up periods. In this paper, we examine the rationale for an atorvastatin-ezetimibe combination, review the evidence supporting it, and discuss its potential role in the management of dyslipidemia.

Keywords

HSM MED Anticholesteremic Agents/administration & dosage Atorvastatin Calcium/administration & dosage Cholesterol, HDL/blood Cholesterol, LDL/blood Drug Therapy, Combination/methods Ezetimibe/administration & dosage Hyperlipidemias/blood Hyperlipidemias/drug therapy Simvastatin/administration & dosage